Mikhail Blagosklonny is a doctor and scientist who pursued research on cancer and aging. He was a former professor on the subject of oncology at the Roswell Park Cancer Institute in New York.
Dr. Blagosklonny graduated from the First Pavlov State Medical university of St. Petersburg, having an M.D. in internal medicine and a PhD in experimental medicine and cardiology. He became the associate professor of medicine at New York Medical College in 2002. He eventually became a senior scientist at the Ordway Research Institute from 2002-2009. He remained a senior scientist in the said institute until he became a professor of oncology at the Roswell Park Cancer Institute.
Being deeply interested in the field of experimental medicine and cancer research, Dr. Blagosklonny’s interests included targeted cancer therapies and strategies to prevent damage in the normal body cells. He has also done research on understanding the biological systems involving aging and how to create anti-aging drugs.
At present, Dr. Mikhail Blagosklonny is the editor-in-chief of the following publications: Aging, Cell Cycle, and Oncotarget. He has participated in many print journals and research, and he is also the current associate editor of Cancer Biology and Therapy. He also contributed as a member of the editorial board in Cell Death and Differentiation.
Dr. Mikhail or “Misha” as called by his colleagues in Roswell Park Cancer Institute is greatly commended for his work. He has led the research and contributed in several journals and articles on medicinal research regarding chronic diseases such as cancer and diabetes. He also released journals on the topics of targeted treatments for cancer, and cell reactions to certain types of drugs.
Dr. Blagosklonny was also involved in a recent ground-breaking anti-aging research. He was able to reveal a substance called Rapamycin and its healing properties. Initially, it was discovered that Rapamycin helps patients by decreasing the chances of organ donor bodily rejections.
His further studies concluded that the drug is able to give out other benefits such as: treatment of cancer, Tuberous Sclerosis Complex (TSC), and facial angiofibromas, increasing longevity, among many others. He is known for promoting the use of the said drug, and the knowledge he provided in the field of cancer and anti-aging research was greatly beneficial to the field.
In essence, Dr. Blagosklonny indicated that the correct amount of dosage of Rapamycin during the experiments improved the lifespan of the subjects. Also, he noted that the research concludes that it will possibly improve human’s ability to age slowly. With the combination of other anti-aging procedures such as bypass surgery, he believes that the drug will be very effective for patient wishing to have a longer, better life.
The medical field is advancing, increasing the number of health problems it continuously solves. The contributions of passionate doctors such as Dr. Mikhail Blagosklonny, along with his team are giant steps to the advancement of cancer research. Cancer and diseases related to aging are one of the most common health ailments of the modern-day society, and Dr. Blagosklonny’s work on this field of study will further improve the available treatment options.